PTAB Grants Kyle Bass' Bid To Review Acorda Drug Patents

Law360, New York (March 14, 2016, 9:24 PM EDT) -- The Patent Trial and Appeal Board on Friday granted requests by a group with close ties to hedge fund manager Kyle Bass to review the validity of four Acorda Therapeutics Inc. patents related to its multiple sclerosis drug Ampyra.

The board agreed to institute inter partes reviews of the four patents, finding the Coalition for Affordable Drugs likely will be able to show that a U.S. Securities and Exchange Commission filing and two publications that predate the claims make them unpatentable because of obviousness, according to...
To view the full article, register now.